Rational selection of hemagglutinin variants of H3N2 influenza viruses in preparation of live influenza vaccine strains to optimize growth characteristics

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Up to date Russian live attenuated influenza vaccines are produced in developing chicken embryos. During passaging in embryos, the virus isolated from the human respiratory tract undergoes adaptation to the receptors in embryos. The population of the virus, at any passage in chicken embryos, is heterogeneous and contains variants of viruses with one or another set of adaptive substitutions. Before preparing the vaccine strain, the population of the epidemic virus is cloned and the genetic sequence of the hemagglutinin and neuraminidase clones is analyzed. The growth characteristics of the vaccine strain and its antigenic properties depend on the correct choice of the variant of the virus.

AIM: The aim of the study was to select the variant of the H3N2 subtype virus for the preparation of a vaccine reassortant based on data on the composition of the population and an assessment of its growth properties.

MATERIALS AND METHODS: Viruses were cloned in developing chicken embryos, sequencing of the hemagglutinin and neuraminidase genes of the clones was performed. On the basis of the clones selected based on the results of the analysis of the population, strains of a live influenza vaccine were obtained by the reassortment in the chicken embryos. The growth characteristics of the strains, the phenotype in eggs, and the antigenic properties by hemagglutination inhibition test were evaluated.

RESULTS: The influenza virus A/Kansas/14/2017 recommended by WHO for the epidemic season 2019-2020 acquired a pair of D190N + N246T substitutions dominating in the population at the 7th passage in eggs. From the population of A/Kansas/14/2017-like strain A/Brisbane/34/2018, from the third passage in the eggs, it was possible to obtain a variant of the virus with substitutions G186V + S219Y in hemagglutinin. The growth characteristics of the strain based on A/Kansas/14/2017 (passage E7) were significantly inferior to the characteristics of the strain based on A/Brisbane/34/2018 (passage E3), in the absence of differences in antigenic properties.

CONCLUSIONS: The variant of egg adaptation of hemagglutinin G186V in strains of clade 3c.3a is preferable for the preparation of live influenza vaccine strains; variant N246T is not optimal. When preparing strains, it is necessary to analyze the composition of the virus population by cloning and choose the most optimal option for preparing strains. The persistence of egg-adaptive substitutions in passaged variants of the virus is not always optimal for strains of live influenza vaccine, and therefore it is preferable to use the population as close as possible to the initial variant to start work on the strain.

Full Text

Restricted Access

About the authors

Ekaterina A. Stepanova

Institute of Experimental Medicine

Author for correspondence.
Email: fedorova.iem@gmail.com
ORCID iD: 0000-0002-8670-8645
SPIN-code: 8010-3047

Cand. Sci. (Biol.), Senior Researcher

Russian Federation, Saint Petersburg

Ekaterina A. Bazhenova

Institute of Experimental Medicine

Email: sonya.01.08@mail.ru
ORCID iD: 0000-0003-3280-556X
SPIN-code: 5169-1426

Cand. Sci. (Biol.), Senior Researcher

Russian Federation, Saint Petersburg

Elena V. Krutikova

Institute of Experimental Medicine

Email: krutikova.iem@gmail.com
ORCID iD: 0000-0002-0383-2625
SPIN-code: 6330-6128

Cand. Sci. (Biol.), Researcher

Russian Federation, Saint Petersburg

Nataliya V. Larionova

Institute of Experimental Medicine

Email: nvlarionova@mail.ru
ORCID iD: 0000-0003-1171-3383
SPIN-code: 4709-5010

Dr. Sci. (Biol.), Leading Researcher

Russian Federation, Saint Petersburg

Irina V. Kiseleva

Institute of Experimental Medicine

Email: irina.v.kiseleva@mail.ru
ORCID iD: 0000-0002-3892-9873
SPIN-code: 7857-7306

Dr. Sci. (Biol.), Professor, Head of the Laboratory

Russian Federation, Saint Petersburg

Larisa G. Rudenko

Institute of Experimental Medicine

Email: vaccine@mail.ru
ORCID iD: 0000-0002-0107-9959
SPIN-code: 4181-1372

Dr. Sci. (Med.), Professor, Honored Scientist of the Russian Federation

Russian Federation, Saint Petersburg

References

  1. Recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season [Internet]. WHO. Available from: https://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/. Accessed: 28.08.2021.
  2. Gouma S, Weirick M, Hensley SE. Antigenic assessment of the H3N2 component of the 2019-2020 Northern Hemisphere influenza vaccine. Nat Commun. 2020;11(1):2445. doi: 10.1038/s41467-020-16183-y
  3. Tate MD, Job ER, Deng YM, et al. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses. 2014;6(3):1294–1316. doi: 10.3390/v6031294

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2021 Stepanova E.A., Bazhenova E.A., Krutikova E.V., Larionova N.V., Kiseleva I.V., Rudenko L.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies